References
Key articles
Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016 Aug 11;2:16057. Abstract
Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab. 2023 Sep 18;108(10):2447-69.Full text Abstract
American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 194: polycystic ovary syndrome. Obstet Gynecol. 2018 Jun;131(6):e157-71. Abstract
Reference articles
1. Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, et al., eds. Polycystic ovary syndrome. Cambridge, MA: Blackwell Scientific; 1992:377-84.
2. The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004 Jan;81(1):19-25. Abstract
3. Azziz R, Carmina E, Dewailly D, et al. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006 Nov;91(11):4237-45.Full text Abstract
4. Azziz R, Carmina E, Dewailly D, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril. 2009 Feb;91(2):456-88. Abstract
5. Norman RJ, Dewailly D, Legro RS, et al. Polycystic ovary syndrome. Lancet. 2007 Aug 25;370(9588):685-97. Abstract
6. Dewailly D, Catteau-Jonard S, Reyss AC, et al. Oligoanovulation with polycystic ovaries but not overt hyperandrogenism. J Clin Endocrinol Metab. 2006 Oct;91(10):3922-7.Full text Abstract
7. Bozdag G, Mumusoglu S, Zengin D, et al. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016 Dec;31(12):2841-55. Abstract
8. Chiaffarino F, Cipriani S, Dalmartello M, et al. Prevalence of polycystic ovary syndrome in European countries and USA: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2022 Dec;279:159-70. Abstract
9. Wu Q, Gao J, Bai D, et al. The prevalence of polycystic ovarian syndrome in Chinese women: a meta-analysis. Ann Palliat Med. 2021 Jan;10(1):74-87.Full text Abstract
10. Wolf WM, Wattick RA, Kinkade ON, et al. Geographical prevalence of polycystic ovary syndrome as determined by region and race/ethnicity. Int J Environ Res Public Health. 2018 Nov 20;15(11):2589.Full text Abstract
11. Lizneva D, Suturina L, Walker W, et al. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016 Jul;106(1):6-15.Full text Abstract
12. Joham AE, Norman RJ, Stener-Victorin E, et al. Polycystic ovary syndrome. Lancet Diabetes Endocrinol. 2022 Sep;10(9):668-80. Abstract
13. Kazemi M, Kim JY, Wan C, et al. Comprehensive evaluation of disparities in cardiometabolic and reproductive risk between Hispanic and White women with polycystic ovary syndrome in the United States: a systematic review and meta-analysis. Am J Obstet Gynecol. 2022 Feb;226(2):187-204.e15. Abstract
14. Azziz R, Sanchez LA, Knochenhauer ES, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004 Feb;89(2):453-62.Full text Abstract
15. Sam S, Sung YA, Legro RS. Evidence for pancreatic beta-cell dysfunction in brothers of women with polycystic ovary syndrome. Metabolism. 2008 Jan;57(1):84-9. Abstract
16. Legro RS, Kunselman AR, Demers L, et al. Elevated dehydroepiandrosterone sulfate levels as the reproductive phenotype in the brothers of women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2002 May;87(5):2134-8.Full text Abstract
17. Goodarzi MO. Looking for polycystic ovary syndrome genes: rational and best strategy. Semin Reprod Med. 2008 Jan;26(1):5-13. Abstract
18. Vink JM, Sadrzadeh S, Lambalk CB, et al. Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab. 2006 Jun;91(6):2100-4.Full text Abstract
19. Chen ZJ, Zhao H, He L, et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat Genet. 2011 Jan;43(1):55-9. Abstract
20. Goodarzi MO, Jones MR, Li X, et al. Replication of association of DENND1A and THADA variants with polycystic ovary syndrome in European cohorts. J Med Genet. 2012 Feb;49(2):90-5. Abstract
21. Eriksen MB, Brusgaard K, Andersen M, et al. Association of polycystic ovary syndrome susceptibility single nucleotide polymorphism rs2479106 and PCOS in Caucasian patients with PCOS or hirsutism as referral diagnosis. Eur J Obstet Gynecol Reprod Biol. 2012 Jul;163(1):39-42. Abstract
22. Welt CK, Styrkarsdottir U, Ehrmann DA, et al. Variants in DENND1A are associated with polycystic ovary syndrome in women of European ancestry. J Clin Endocrinol Metab. 2012 Jul;97(7):E1342-7.Full text Abstract
23. Bao S, Cai JH, Yang SY, et al. Association of DENND1A gene polymorphisms with polycystic ovary syndrome: a meta-analysis. J Clin Res Pediatr Endocrinol. 2016 Jun 5;8(2):135-43.Full text Abstract
24. Shi Y, Zhao H, Shi Y, et al. Genome-wide association study identifies eight new risk loci for polycystic ovary syndrome. Nat Genet. 2012 Sep;44(9):1020-5. Abstract
25. Day F, Karaderi T, Jones MR, et al. Large-scale genome-wide meta-analysis of polycystic ovary syndrome suggests shared genetic architecture for different diagnosis criteria. PLoS Genet. 2018 Dec 19;14(12):e1007813.Full text Abstract
26. Zhang Y, Ho K, Keaton JM, et al. A genome-wide association study of polycystic ovary syndrome identified from electronic health records. Am J Obstet Gynecol. 2020 Oct;223(4):559.e1-559.e21. Abstract
27. Tyrmi JS, Arffman RK, Pujol-Gualdo N, et al. Leveraging Northern European population history: novel low-frequency variants for polycystic ovary syndrome. Hum Reprod. 2022 Jan 28;37(2):352-65.Full text Abstract
28. Azziz R, Dumesic DA, Goodarzi MO. Polycystic ovary syndrome: an ancient disorder? Fertil Steril. 2011 Apr;95(5):1544-8.Full text Abstract
29. Shah NA, Antoine HJ, Pall M, et al. Association of androgen receptor CAG repeat polymorphism and polycystic ovary syndrome. J Clin Endocrinol Metab. 2008 May;93(5):1939-45.Full text Abstract
30. Hickey TE, Legro RS, Norman RJ. Epigenetic modification of the X chromosome influences susceptibility to polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 Jul;91(7):2789-91.Full text Abstract
31. Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016 Aug 11;2:16057. Abstract
32. Kahsar-Miller MD, Nixon C, Boots LR, et al. Prevalence of polycystic ovary syndrome (PCOS) in first-degree relatives of patients with PCOS. Fertil Steril. 2001 Jan;75(1):53-8. Abstract
33. Legro RS, Driscoll D, Strauss JF III, et al. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci USA. 1998 Dec 8;95(25):14956-60.Full text Abstract
34. Goodarzi MO, Azziz R. Diagnosis, epidemiology, and genetics of the polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab. 2006 Jun;20(2):193-205. Abstract
35. Ibáñez L, Dimartino-Nardi J, Potau N, et al. Premature adrenarche-normal variant or forerunner of adult disease? Endocr Rev. 2000 Dec;21(6):671-96.Full text Abstract
36. Day FR, Hinds DA, Tung JY, et al. Causal mechanisms and balancing selection inferred from genetic associations with polycystic ovary syndrome. Nat Commun. 2015 Sep 29;6:8464.Full text Abstract
37. Brower MA, Hai Y, Jones MR, et al. Bidirectional Mendelian randomization to explore the causal relationships between body mass index and polycystic ovary syndrome. Hum Reprod. 2019 Jan 1;34(1):127-36. Abstract
38. Dobbie LJ, Pittam B, Zhao SS, et al. Childhood, adolescent, and adulthood adiposity are associated with risk of PCOS: a Mendelian randomization study with meta-analysis. Hum Reprod. 2023 Jun 1;38(6):1168-82.Full text Abstract
39. Ibáñez L, Potau N, Francois I, et al. Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: relation to reduced fetal growth. J Clin Endocrinol Metab. 1998 Oct;83(10):3558-62.Full text Abstract
40. Ibáñez L, Valls C, Potau N, et al. Polycystic ovary syndrome after precocious pubarche: ontogeny of the low-birthweight effect. Clin Endocrinol (Oxf). 2001 Nov;55(5):667-72. Abstract
41. Melo AS, Vieira CS, Barbieri MA, et al. High prevalence of polycystic ovary syndrome in women born small for gestational age. Hum Reprod. 2010 Aug;25(8):2124-31. Abstract
42. Valgeirsdottir H, Vanky E, Sundström-Poromaa I, et al. Prenatal exposures and birth indices, and subsequent risk of polycystic ovary syndrome: a national registry-based cohort study. BJOG. 2019 Jan;126(2):244-51. Abstract
43. Barnes RB, Rosenfield RL, Ehrmann DA, et al. Ovarian hyperandrogynism as a result of congenital adrenal virilizing disorders: evidence for perinatal masculinization of neuroendocrine function in women. J Clin Endocrinol Metab. 1994 Nov;79(5):1328-33. Abstract
44. Kuijper EA, Vink JM, Lambalk CB, et al. Prevalence of polycystic ovary syndrome in women from opposite-sex twin pairs. J Clin Endocrinol Metab. 2009 Jun;94(6):1987-90. Abstract
45. Anderson H, Fogel N, Grebe SK, et al. Infants of women with polycystic ovary syndrome have lower cord blood androstenedione and estradiol levels. J Clin Endocrinol Metab. 2010 May;95(5):2180-6. Abstract
46. Barry JA, Kay AR, Navaratnarajah R, et al. Umbilical vein testosterone in female infants born to mothers with polycystic ovary syndrome is elevated to male levels. J Obstet Gynaecol. 2010;30(5):444-6. Abstract
47. Kandaraki E, Chatzigeorgiou A, Livadas S, et al. Endocrine disruptors and polycystic ovary syndrome (PCOS): elevated serum levels of bisphenol A in women with PCOS. J Clin Endocrinol Metab. 2011 Mar;96(3):E480-4. Abstract
48. Hu Y, Wen S, Yuan D, et al. The association between the environmental endocrine disruptor bisphenol A and polycystic ovary syndrome: a systematic review and meta-analysis. Gynecol Endocrinol. 2018 May;34(5):370-7. Abstract
49. Srnovršnik T, Virant-Klun I, Pinter B. Polycystic ovary syndrome and endocrine disruptors (bisphenols, parabens, and triclosan)-a systematic review. Life (Basel). 2023 Jan 4;13(1):138.Full text Abstract
50. Anon. Screening and management of the hyperandrogenic adolescent: ACOG committee opinion, number 789. Obstet Gynecol. 2019 Oct;134(4):e106-14.Full text Abstract
51. Peña AS, Witchel SF, Hoeger KM, et al. Adolescent polycystic ovary syndrome according to the international evidence-based guideline. BMC Med. 2020 Mar 24;18(1):72.Full text Abstract
52. Ibáñez L, Oberfield SE, Witchel S, et al. An International Consortium update: pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence. Horm Res Paediatr. 2017;88(6):371-95.Full text Abstract
53. Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab. 2023 Sep 18;108(10):2447-69.Full text Abstract
54. Meczekalski B, Niwczyk O, Kostrzak A, et al. PCOS in adolescents-ongoing riddles in diagnosis and treatment. J Clin Med. 2023 Feb 3;12(3):1221.Full text Abstract
55. Vassalou H, Sotiraki M, Michala L. PCOS diagnosis in adolescents: the timeline of a controversy in a systematic review. J Pediatr Endocrinol Metab. 2019 Jun 26;32(6):549-59. Abstract
56. Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012 Jan;97(1):28-38.e25. Abstract
57. Wild RA, Carmina E, Amanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab. 2010 May;95(5):2038-49.Full text Abstract
58. Alsamarai S, Adams JM, Murphy MK, et al. Criteria for polycystic ovarian morphology in polycystic ovary syndrome as a function of age. J Clin Endocrinol Metab. 2009 Dec;94(12):4961-70. Abstract
59. Anand S, Kumar A, Prasad A, et al. Updated meta-analysis on the diagnostic accuracy of serum anti-Mullerian hormone in poly cystic ovary syndrome involving 13 509 subjects. J Obstet Gynaecol Res. 2022 Aug;48(8):2162-74. Abstract
60. Legro RS, Schlaff WD, Diamond MP, et al. Total testosterone assays in women with polycystic ovary syndrome: precision and correlation with hirsutism. J Clin Endocrinol Metab. 2010 Dec;95(12):5305-13.Full text Abstract
61. Ayala C, Steinberger E, Smith KD, et al. Serum testosterone levels and reference ranges in reproductive-age women. Endocr Pract. 1999 Nov-Dec;5(6):322-9. Abstract
62. Bui HN, Sluss PM, Hayes FJ, et al. Testosterone, free testosterone, and free androgen index in women: Reference intervals, biological variation, and diagnostic value in polycystic ovary syndrome. Clin Chim Acta. 2015 Oct 23;450:227-32. Abstract
63. Woods KS, Reyna R, Azziz R. Effect of oral micronized progesterone on androgen levels in women with polycystic ovary syndrome. Fertil Steril. 2002 Jun;77(6):1125-7. Abstract
64. American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin No. 194: polycystic ovary syndrome. Obstet Gynecol. 2018 Jun;131(6):e157-71. Abstract
65. Kakoly NS, Khomami MB, Joham AE, et al. Ethnicity, obesity and the prevalence of impaired glucose tolerance and type 2 diabetes in PCOS: a systematic review and meta-regression. Hum Reprod Update. 2018 Jul 1;24(4):455-67.Full text Abstract
66. Salley KE, Wickham EP, Cheang KI, et al. Glucose intolerance in polycystic ovary syndrome: a position statement of the Androgen Excess Society. J Clin Endocrinol Metab. 2007 Dec;92(12):4546-56.Full text Abstract
67. De Ugarte CM, Chen YDI, Azziz R. What's the best way to diagnose insulin resistance and hyperinsulinemia? Contemp Ob Gyn. 2005 March;50:66-74.
68. Hanna F, Wu P, Heald A, et al. Diabetes detection in women with gestational diabetes and polycystic ovarian syndrome. BMJ. 2023 Jul 4;382:e071675.Full text Abstract
69. Elting MW, Kwee J, Korsen TJ, et al. Aging women with polycystic ovary syndrome who achieve regular menstrual cycles have a smaller follicle cohort than those who continue to have irregular cycles. Fertil Steril. 2003 May;79(5):1154-60. Abstract
70. Kim JJ, Choi YM. Phenotype and genotype of polycystic ovary syndrome in Asia: Ethnic differences. J Obstet Gynaecol Res. 2019 Dec;45(12):2330-7. Abstract
71. Azziz R, Hincapie LA, Knochenhauer ES, et al. Screening for 21-hydroxylase-deficient nonclassic adrenal hyperplasia among hyperandrogenic women: a prospective study. Fertil Steril. 1999 Nov;72(5):915-25. Abstract
72. Wild RA, Applebaum-Bowden D, Demers LM, et al. Lipoprotein lipids in women with androgen excess: independent associations with increased insulin and androgen. Clin Chem. 1990 Feb;36(2):283-9. Abstract
73. Talbott E, Clerici A, Berga SL, et al. Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. J Clin Epidemiol. 1998 May;51(5):415-22. Abstract
74. Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med. 2001 Dec 1;111(8):607-13. Abstract
75. Meldrum DR, Abraham GE. Peripheral and ovarian venous concentrations of various steroid hormones in virilizing ovarian tumors. Obstet Gynecol. 1979 Jan;53(1):36-43. Abstract
76. Derksen J, Nagesser SK, Meinders AE. Identification of virilizing adrenal tumors in hirsute women. N Engl J Med. 1994 Oct 13;331(15):968-73.Full text Abstract
77. Draper N, Stewart PM. 11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. J Endocrinol. 2005 Aug;186(2):251-71. Abstract
78. Martin KA, Anderson RR, Chang RJ, et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018 Apr 1;103(4):1233-57.Full text Abstract
79. Goodman NF, Cobin RH, Futterweit W, et al. American Association Of Clinical Endocrinologists, American College Of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome - part 1. Endocr Pract. 2015 Nov;21(11):1291-300. Abstract
80. Goodman NF, Cobin RH, Futterweit W, et al. American Association Of Clinical Endocrinologists, American College Of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome - part 2. Endocr Pract. 2015 Dec;21(12):1415-26. Abstract
81. Butt MS, Saleem J, Zakar R, et al. Benefits of physical activity on reproductive health functions among polycystic ovarian syndrome women: a systematic review. BMC Public Health. 2023 May 12;23(1):882.Full text Abstract
82. Abdolahian S, Tehrani FR, Amiri M, et al. Effect of lifestyle modifications on anthropometric, clinical, and biochemical parameters in adolescent girls with polycystic ovary syndrome: a systematic review and meta-analysis. BMC Endocr Disord. 2020 May 19;20(1):71.Full text Abstract
83. Kiddy DS, Hamilton-Fairley D, Bush A, et al. Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin Endocrinol (Oxf). 1992 Jan;36(1):105-11. Abstract
84. Harrison CL, Lombard CB, Moran LJ, et al. Exercise therapy in polycystic ovary syndrome: a systematic review. Hum Reprod Update. 2011 Mar-Apr;17(2):171-83.Full text Abstract
85. Lim SS, Hutchison SK, Van Ryswyk E, et al. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2019 Mar 28;(3):CD007506.Full text Abstract
86. Oberg E, Gidlöf S, Jakson I, et al. Improved menstrual function in obese women with polycystic ovary syndrome after behavioural modification intervention - a randomized controlled trial. Clin Endocrinol (Oxf). 2019 Mar;90(3):468-78. Abstract
87. Yang ST, Liu CH, Ma SH, et al. Association between pre-pregnancy overweightness/obesity and pregnancy outcomes in women with polycystic ovary syndrome: A Systematic Review and Meta-Analysis. Int J Environ Res Public Health. 2022 Jul 26;19(15):9094.Full text Abstract
88. Lie Fong S, Douma A, Verhaeghe J. Implementing the international evidence-based guideline of assessment and management of polycystic ovary syndrome (PCOS): how to achieve weight loss in overweight and obese women with PCOS? J Gynecol Obstet Hum Reprod. 2021 Jun;50(6):101894. Abstract
89. Wang R, Li W, Bordewijk EM, et al. First-line ovulation induction for polycystic ovary syndrome: an individual participant data meta-analysis. Hum Reprod Update. 2019 Nov 5;25(6):717-32.Full text Abstract
90. Franik S, Le QK, Kremer JA, et al. Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2022 Sep 27;9(9):CD010287.Full text Abstract
91. Liu Z, Geng Y, Huang Y, et al. Letrozole compared with clomiphene citrate for polycystic ovarian syndrome: a systematic review and meta-analysis. Obstet Gynecol. 2023 Mar 1;141(3):523-34. Abstract
92. Smithson DS, Vause TDR, Cheung AP. No. 362-ovulation induction in polycystic ovary syndrome. J Obstet Gynaecol Can. 2018 Jul;40(7):978-87. Abstract
93. Casper RF, Mitwally MF. Review: aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab. 2006 Mar;91(3):760-71.Full text Abstract
94. Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014 Jul 10;371(2):119-29.Full text Abstract
95. Misso ML, Wong JL, Teede HJ, et al. Aromatase inhibitors for PCOS: a systematic review and meta-analysis. Hum Reprod Update. 2012 May-Jun;18(3):301-12. Abstract
96. Yu Q, Hu S, Wang Y, et al. Letrozole versus laparoscopic ovarian drilling in clomiphene citrate-resistant women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Reprod Biol Endocrinol. 2019 Feb 6;17(1):17.Full text Abstract
97. Abu Hashim H, Shokeir T, Badawy A. Letrozole versus combined metformin and clomiphene citrate for ovulation induction in clomiphene-resistant women with polycystic ovary syndrome: a randomized controlled trial. Fertil Steril. 2010 Sep;94(4):1405-9. Abstract
98. Ehrmann DA, Cavaghan MK, Imperial J, et al. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1997 Feb;82(2):524-30.Full text Abstract
99. Johnson NP, Bontekoe S, Stewart AW. Analysis of factors predicting success of metformin and clomiphene treatment for women with infertility owing to PCOS-related ovulation dysfunction in a randomised controlled trial. Aust N Z J Obstet Gynaecol. 2011 Jun;51(3):252-6. Abstract
100. Sharpe A, Morley LC, Tang T, et al. Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2019 Dec 17;(12):CD013505.Full text Abstract
101. Magzoub R, Kheirelseid EAH, Perks C, et al. Does metformin improve reproduction outcomes for non-obese, infertile women with polycystic ovary syndrome? Meta-analysis and systematic review. Eur J Obstet Gynecol Reprod Biol. 2022 Apr;271:38-62. Abstract
102. Tan X, Li S, Chang Y, Fang C, et al. Effect of metformin treatment during pregnancy on women with PCOS: a systematic review and meta-analysis. Clin Invest Med. 2016 Sep 11;39(4):E120-31. Abstract
103. Tarry-Adkins JL, Ozanne SE, Aiken CE. Impact of metformin treatment during pregnancy on maternal outcomes: a systematic review/meta-analysis. Sci Rep. 2021 Apr 29;11(1):9240.Full text Abstract
104. Abolhassani N, Winterfeld U, Kaplan YC, et al. Major malformations risk following early pregnancy exposure to metformin: a systematic review and meta-analysis. BMJ Open Diabetes Res Care. 2023 Jan;11(1):e002919.Full text Abstract
105. Hanem LGE, Salvesen Ø, Juliusson PB, et al. Intrauterine metformin exposure and offspring cardiometabolic risk factors (PedMet study): a 5-10 year follow-up of the PregMet randomised controlled trial. Lancet Child Adolesc Health. 2019 Mar;3(3):166-74. Abstract
106. Brown J, Farquhar C. Clomiphene and other antioestrogens for ovulation induction in polycystic ovarian syndrome. Cochrane Database Syst Rev. 2016 Dec 15;(12):CD002249.Full text Abstract
107. Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med. 2007 Feb 8;356(6):551-66. Abstract
108. Ding N, Chang J, Jian Q, et al. Luteal phase clomiphene citrate for ovulation induction in women with polycystic ovary syndrome: a systematic review and meta-analysis. Gynecol Endocrinol. 2016 Nov;32(11):866-71. Abstract
109. Lin W, Feng J, Zhou H, et al. Therapeutic efficacy of clomiphene citrate combined with metformin in patients with polycystic ovary syndrome. J Clin Pharm Ther. 2022 Mar;47(3):321-9. Abstract
110. Moll E, Bossuyt PM, Korevaar JC, et al. Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ. 2006 Jun 24;332(7556):1485.Full text Abstract
111. Cataldo NA, Barnhart HX, Legro RS, et al. Extended-release metformin does not reduce the clomiphene citrate dose required to induce ovulation in polycystic ovary syndrome. J Clin Endocrinol Metab. 2008 Aug;93(8):3124-7.Full text Abstract
112. Moll E, Korevaar JC, Bossuyt PM, et al. Does adding metformin to clomifene citrate lead to higher pregnancy rates in a subset of women with polycystic ovary syndrome? Hum Reprod. 2008 Aug;23(8):1830-4.Full text Abstract
113. Moll E, van der Veen F, van Wely M. The role of metformin in polycystic ovary syndrome: a systematic review. Hum Reprod Update. 2007 Nov-Dec;13(6):527-37.Full text Abstract
114. Creanga AA, Bradley HM, McCormick C, et al. Use of metformin in polycystic ovary syndrome: a meta-analysis. Obstet Gynecol. 2008 Apr;111(4):959-68. Abstract
115. Weiss NS, Kostova E, Nahuis M, et al. Gonadotrophins for ovulation induction in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2019 Jan 16;1:CD010290.Full text Abstract
116. Christin-Maitre S, Hugues JN. A comparative randomized multicentric study comparing the step-up versus step-down protocol in polycystic ovary syndrome. Hum Reprod. 2003 Aug;18(8):1626-31.Full text Abstract
117. Koundouros SN. A comparison study of a novel stimulation protocol and the conventional low dose step-up and step-down regimens in patients with polycystic ovary syndrome undergoing in vitro fertilization. Fertil Steril. 2008 Sep;90(3):569-75. Abstract
118. Aboulghar M. Symposium: Update on prediction and management of OHSS. Prevention of OHSS. Reprod Biomed Online. 2009 Jul;19(1):33-42. Abstract
119. Notaro ALG, Neto FTL. The use of metformin in women with polycystic ovary syndrome: an updated review. J Assist Reprod Genet. 2022 Mar;39(3):573-9. Abstract
120. Bordewijk EM, Nahuis M, Costello MF, et al. Metformin during ovulation induction with gonadotrophins followed by timed intercourse or intrauterine insemination for subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev. 2017 Jan 24;(1):CD009090.Full text Abstract
121. Abu Hashim H. Twenty years of ovulation induction with metformin for PCOS; what is the best available evidence? Reprod Biomed Online. 2016 Jan;32(1):44-53. Abstract
122. Fernandez H, Morin-Surruca M, Torre A, et al. Ovarian drilling for surgical treatment of polycystic ovarian syndrome: a comprehensive review. Reprod Biomed Online. 2011 Jun;22(6):556-68. Abstract
123. Bordewijk EM, Ng KYB, Rakic L, et al. Laparoscopic ovarian drilling for ovulation induction in women with anovulatory polycystic ovary syndrome. Cochrane Database Syst Rev. 2020 Feb 11;(2):CD001122.Full text Abstract
124. Api M. Is ovarian reserve diminished after laparoscopic ovarian drilling? Gynecol Endocrinol. 2009 Mar;25(3):159-65. Abstract
125. Abu Hashim H, Foda O, El Rakhawy M. Unilateral or bilateral laparoscopic ovarian drilling in polycystic ovary syndrome: a meta-analysis of randomized trials. Arch Gynecol Obstet. 2018 Apr;297(4):859-70. Abstract
126. Baghdadi LR, Abu Hashim H, Amer SA, et al. Impact of obesity on reproductive outcomes after ovarian ablative therapy in PCOS: a collaborative meta-analysis. Reprod Biomed Online. 2012 Sep;25(3):227-41.Full text Abstract
127. Hueb CK, Dias Júnior JA, Abrão MS, et al. Drilling: medical indications and surgical technique. Rev Assoc Med Bras (1992). 2015 Nov-Dec;61(6):530-5. Abstract
128. Tang K, Wu L, Luo Y, et al. In vitro fertilization outcomes in women with polycystic ovary syndrome: A meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2021 Apr;259:146-52. Abstract
129. Matorras R, Pijoan JI, Laínz L, et al. Polycystic ovarian syndrome and miscarriage in IVF: systematic revision of the literature and meta-analysis. Arch Gynecol Obstet. 2023 Aug;308(2):363-77. Abstract
130. Palomba S, Falbo A, La Sala GB. Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. BJOG. 2013 Feb;120(3):267-76. Abstract
131. Mourad S, Brown J, Farquhar C. Interventions for the prevention of OHSS in ART cycles: an overview of Cochrane reviews. Cochrane Database Syst Rev. 2017 Jan 23;(1):CD012103.Full text Abstract
132. Huang X, Wang P, Tal R, et al. A systematic review and meta-analysis of metformin among patients with polycystic ovary syndrome undergoing assisted reproductive technology procedures. Int J Gynaecol Obstet. 2015 Nov;131(2):111-6. Abstract
133. Barrionuevo P, Nabhan M, Altayar O, et al. Treatment options for hirsutism: a systematic review and network meta-analysis. J Clin Endocrinol Metab. 2018 Apr 1;103(4):1258-64. Abstract
134. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, et al. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ. 2009 Aug 13;339:b2921. Abstract
135. Lidegaard Ø, Løkkegaard E, Svendsen AL, et al. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ. 2009 Aug 13;339:b2890.Full text Abstract
136. Gronich N, Lavi I, Rennert G. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. CMAJ. 2011 Dec 13;183(18):E1319-25.Full text Abstract
137. Dinger JC, Heinemann LA, Kühl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception. 2007 May;75(5):344-54. Abstract
138. ACOG Practice Bulletin No. 206: Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol. 2019 Feb;133(2):e128-50. Abstract
139. Barba M, Schünemann HJ, Sperati F, et al. The effects of metformin on endogenous androgens and SHBG in women: a systematic review and meta-analysis. Clin Endocrinol (Oxf). 2009 May;70(5):661-70.Full text Abstract
140. Tang Z, Guan J, Mao JH, et al. Quantitative risk-benefit profiles of oral contraceptives, insulin sensitizers and antiandrogens for women with polycystic ovary syndrome: A model-based meta-analysis. Eur J Pharm Sci. 2023 Nov 1;190:106577. Abstract
141. Fraison E, Kostova E, Moran LJ, et al. Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome. Cochrane Database Syst Rev. 2020 Aug 13;(8):CD005552.Full text Abstract
142. Yen H, Chang YT, Yee FJ, et al. Metformin therapy for acne in patients with polycystic ovary syndrome: a systematic review and meta-analysis. Am J Clin Dermatol. 2021 Jan;22(1):11-23. Abstract
143. Zeng H, Zhang Y, Huang S, et al. Metformin combined with spironolactone vs. metformin alone in polycystic ovary syndrome: a meta-analysis. Front Endocrinol (Lausanne). 2023;14:1223768.Full text Abstract
144. Nieuwenhuis-Ruifrok AE, Kuchenbecker WK, Hoek A, et al. Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis. Hum Reprod Update. 2009 Jan-Feb;15(1):57-68.Full text Abstract
145. Wolf JE Jr, Shander D, Huber F, et al. Randomized, double-blind clinical evaluation of the efficacy and safety of topical eflornithine HCl 13.9% cream in the treatment of women with facial hair. Int J Dermatol. 2007 Jan;46(1):94-8. Abstract
146. Carmina E, Azziz R, Bergfeld W, et al. Female pattern hair loss and androgen excess: a report from the multidisciplinary androgen excess and PCOS committee. J Clin Endocrinol Metab. 2019 Jul 1;104(7):2875-91.Full text Abstract
147. Aubuchon M, Kunselman AR, Schlaff WD, et al. Metformin and/or clomiphene do not adversely affect liver or renal function in women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2011 Oct;96(10):E1645-9. Abstract
148. Tso LO, Costello MF, Albuquerque LET, et al. Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2020 Dec 21;(12):CD006105.Full text Abstract
149. Yildiz BO. Oral contraceptives in polycystic ovary syndrome: risk-benefit assessment. Semin Reprod Med. 2008 Jan;26(1):111-20. Abstract
150. Zhang YY, Hou LQ, Zhao TY. Effects of acarbose on polycystic ovary syndrome: a meta-analysis. Exp Clin Endocrinol Diabetes. 2014 Jun;122(6):373-8. Abstract
151. Banaszewska B, Pawelczyk L, Spaczynski RZ, et al. Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. J Clin Endocrinol Metab. 2007 Feb;92(2):456-61.Full text Abstract
152. Liu Y, Shao Y, Xie J, et al. The efficacy and safety of metformin combined with simvastatin in the treatment of polycystic ovary syndrome: a meta-analysis and systematic review. Medicine (Baltimore). 2021 Aug 6;100(31):e26622.Full text Abstract
153. Shawish MI, Bagheri B, Musini VM, et al. Effect of atorvastatin on testosterone levels. Cochrane Database Syst Rev. 2021 Jan 22;1(1):CD013211.Full text Abstract
154. Xiong T, Fraison E, Kolibianaki E, et al. Statins for women with polycystic ovary syndrome not actively trying to conceive. Cochrane Database Syst Rev. 2023 Jul 18;7(7):CD008565. Abstract
155. Puurunen J, Piltonen T, Puukka K, et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab. 2013 Dec;98(12):4798-807. Abstract
156. Chen LL, Zheng JH. Effects of atorvastatin on the insulin resistance in women of polycystic ovary syndrome: a systematic review and meta-analysis. Medicine (Baltimore). 2021 Jun 18;100(24):e26289.Full text Abstract
157. Goodarzi MO, Li X, Krauss RM, et al. Relationship of sex to diabetes risk in statin trials. Diabetes Care. 2013 Jul;36(7):e100-1.Full text Abstract
158. Guan C, Zahid S, Minhas AS, et al. Polycystic ovary syndrome: a "risk-enhancing" factor for cardiovascular disease. Fertil Steril. 2022 May;117(5):924-35.Full text Abstract
159. Moran JL, Brinkworth GD, Norman RJ. Dietary therapy in polycystic ovary syndrome. Semin Reprod Med. 2008 Jan;26(1):85-92. Abstract
160. Tziomalos K, Krassas GE, Tzotzas T. The use of sibutramine in the management of obesity and related disorders: an update. Vasc Health Risk Manag. 2009;5(1):441-52.Full text Abstract
161. Abdalla MA, Shah N, Deshmukh H, et al. Impact of pharmacological interventions on anthropometric indices in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Clin Endocrinol (Oxf). 2022 Jun;96(6):758-80.Full text Abstract
162. Chen Z, Cai Z. Effects of oral contraceptives plus orlistat in patients with polycystic ovary syndrome and overweight/obesity: a meta-analysis. J Obstet Gynaecol Res. 2022 Jun;48(6):1399-1408. Abstract
163. Yue W, Huang X, Zhang W, et al. Metabolic surgery on patients with polycystic ovary syndrome: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2022;13:848947.Full text Abstract
164. Luo P, Su Z, Li P, et al. Effects of sleeve gastrectomy on patients with obesity and polycystic ovary syndrome: a meta-analysis. Obes Surg. 2023 Aug;33(8):2335-41. Abstract
165. Skubleny D, Switzer NJ, Gill RS, et al. The impact of bariatric surgery on polycystic ovary syndrome: a systematic review and meta-analysis. Obes Surg. 2016 Jan;26(1):169-76. Abstract
166. Chang C, Chang S, Poles J, et al. The impact of bariatric surgery compared to metformin therapy on pregnancy outcomes in patients with polycystic ovarian syndrome: a systematic review and meta-analysis. J Gastrointest Surg. 2021 Feb;25(2):378-86. Abstract
167. Bayram N, van Wely M, van der Veen F. Pulsatile gonadotrophin releasing hormone for ovulation induction in subfertility associated with polycystic ovary syndrome. Cochrane Database Syst Rev. 2003;(3):CD000412.Full text Abstract
168. Chian RC, Buckett WM, Abdul Jalil AK, et al. Natural-cycle in vitro fertilization combined with in vitro maturation of immature oocytes is a potential approach in infertility treatment. Fertil Steril. 2004 Dec;82(6):1675-8. Abstract
169. Siristatidis CS, Maheshwari A, Vaidakis D, et al. In vitro maturation in subfertile women with polycystic ovarian syndrome undergoing assisted reproduction. Cochrane Database Syst Rev. 2018 Nov 18;(11):CD006606.Full text Abstract
170. Siristatidis C, Sergentanis TN, Vogiatzi P, et al. In vitro maturation in women with vs. without polycystic ovarian syndrome: a systematic review and meta-analysis. PLoS One. 2015 Aug 4;10(8):e0134696.Full text Abstract
171. Chen ZJ, Shi Y, Sun Y, et al. Fresh versus frozen embryos for infertility in the polycystic ovary syndrome. N Engl J Med. 2016 Aug 11;375(6):523-33.Full text Abstract
172. Zhang B, Wei D, Legro RS, et al. Obstetric complications after frozen versus fresh embryo transfer in women with polycystic ovary syndrome: results from a randomized trial. Fertil Steril. 2018 Feb;109(2):324-9. Abstract
173. Lim CED, Ng RWC, Cheng NCL, et al. Acupuncture for polycystic ovarian syndrome. Cochrane Database Syst Rev. 2019 Jul 2;(7):CD007689.Full text Abstract
174. Jo J, Lee YJ. Effectiveness of acupuncture in women with polycystic ovarian syndrome undergoing in vitro fertilisation or intracytoplasmic sperm injection: a systematic review and meta-analysis. Acupunct Med. 2017 Jun;35(3):162-70. Abstract
175. Yun L, Liqun W, Shuqi Y, et al. Acupuncture for infertile women without undergoing assisted reproductive techniques (ART): a systematic review and meta-analysis. Medicine (Baltimore). 2019 Jul;98(29):e16463.Full text Abstract
176. Wu XK, Stener-Victorin E, Kuang HY, et al. Effect of acupuncture and clomiphene in Chinese women with polycystic ovary syndrome: a randomized clinical trial. JAMA. 2017 Jun 27;317(24):2502-14.Full text Abstract
177. Morley LC, Tang T, Yasmin E, et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility. Cochrane Database Syst Rev. 2017 Nov 29;11(11):CD003053.Full text Abstract
178. Li XJ, Yu YX, Liu CQ, et al. Metformin vs thiazolidinediones for treatment of clinical, hormonal and metabolic characteristics of polycystic ovary syndrome: a meta-analysis. Clin Endocrinol (Oxf). 2011 Mar;74(3):332-9. Abstract
179. Zhao H, Xing C, Zhang J, et al. Comparative efficacy of oral insulin sensitizers metformin, thiazolidinediones, inositol, and berberine in improving endocrine and metabolic profiles in women with PCOS: a network meta-analysis. Reprod Health. 2021 Aug 18;18(1):171.Full text Abstract
180. Ge JJ, Wang DJ, Song W, et al. The effectiveness and safety of liraglutide in treating overweight/obese patients with polycystic ovary syndrome: a meta-analysis. J Endocrinol Invest. 2022 Feb;45(2):261-73. Abstract
181. Ye ZR, Yan CQ, Liao N, et al. The Effectiveness and safety of exenatide versus metformin in patients with polycystic ovary syndrome: a meta-Aanalysis of randomized controlled Ttrials. Reprod Sci. 2023 Aug;30(8):2349-61.Full text Abstract
182. Lamos EM, Malek R, Davis SN. GLP-1 receptor agonists in the treatment of polycystic ovary syndrome. Expert Rev Clin Pharmacol. 2017 Apr;10(4):401-8. Abstract
183. Jensterle M, Janez A, Fliers E, et al. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective. Hum Reprod Update. 2019 Jul 1;25(4):504-17.Full text Abstract
184. Carmina E, Longo RA. Semaglutide treatment of excessive body weight in obese PCOS patients unresponsive to lifestyle programs. J Clin Med. 2023 Sep 12;12(18):5921.Full text Abstract
185. American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 194: polycystic ovary syndrome. Obstet Gynecol. 2018 Jun;131(6):e157-71. Abstract
186. Moran LJ, Pasquali R, Teede HJ, et al. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril. 2009 Dec;92(6):1966-82. Abstract
187. Conway G, Dewailly D, Diamanti-Kandarakis E, et al. The polycystic ovary syndrome: a position statement from the European Society of Endocrinology. Eur J Endocrinol. 2014 Oct;171(4):P1-29.Full text Abstract
188. Wenger NK, Lloyd-Jones DM, Elkind MSV, et al. Call to action for cardiovascular disease in women: epidemiology, awareness, access, and delivery of equitable health care: a presidential advisory from the American Heart Association. Circulation. 2022 Jun 7;145(23):e1059-71.Full text Abstract
189. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002 Feb 7;346(6):393-403.Full text Abstract
190. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998 Sep 12;352(9131):854-65. Abstract
191. Pinola P, Piltonen TT, Puurunen J, et al. Androgen profile through life in women with polycystic ovary syndrome: a Nordic multicenter collaboration study. J Clin Endocrinol Metab. 2015 Sep;100(9):3400-7.Full text Abstract
192. Brown ZA, Louwers YV, Fong SL, et al. The phenotype of polycystic ovary syndrome ameliorates with aging. Fertil Steril. 2011 Nov;96(5):1259-65.Full text Abstract
193. Millán-de-Meer M, Luque-Ramírez M, Nattero-Chávez L, et al. PCOS during the menopausal transition and after menopause: a systematic review and meta-analysis. Hum Reprod Update. 2023 Nov 2;29(6):741-72. Abstract
194. Boomsma CM, Eijkemans MJ, Hughes EG, et al. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update. 2006 Nov-Dec;12(6):673-83.Full text Abstract
195. Yu HF, Chen HS, Rao DP, et al. Association between polycystic ovary syndrome and the risk of pregnancy complications: a PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2016 Dec;95(51):e4863. Abstract
196. Wang T, Fu H, Chen L, et al. Pregnancy complications among women with polycystic ovary syndrome in China: a meta-analysis [in Chinese]. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2017 Nov 28;42(11):1300-10. Abstract
197. Bahri Khomami M, Joham AE, Boyle JA, et al. Increased maternal pregnancy complications in polycystic ovary syndrome appear to be independent of obesity-a systematic review, meta-analysis, and meta-regression. Obes Rev. 2019 May;20(5):659-74. Abstract
198. Khorshidi A, Azami M, Tardeh S, et al. The prevalence of metabolic syndrome in patients with polycystic ovary syndrome: a systematic review and meta-analysis. Diabetes Metab Syndr. 2019 Jul - Aug;13(4):2747-53. Abstract
199. Fu L, Xie N, Qu F, et al. The association between polycystic ovary syndrome and metabolic syndrome in adolescents: a systematic review and meta-analysis. Reprod Sci. 2023 Jan;30(1):28-40.Full text Abstract
200. Lim SS, Kakoly NS, Tan JWJ, et al. Metabolic syndrome in polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Obes Rev. 2019 Feb;20(2):339-52. Abstract
201. Cassar S, Misso ML, Hopkins WG, et al. Insulin resistance in polycystic ovary syndrome: a systematic review and meta-analysis of euglycaemic-hyperinsulinaemic clamp studies. Hum Reprod. 2016 Nov;31(11):2619-31.Full text Abstract
202. Behboudi-Gandevani S, Ramezani Tehrani F, Rostami Dovom M, et al. Insulin resistance in obesity and polycystic ovary syndrome: systematic review and meta-analysis of observational studies. Gynecol Endocrinol. 2016;32(5):343-53. Abstract
203. Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999 Jan;22(1):141-6. Abstract
204. Zhu S, Zhang B, Jiang X, et al. Metabolic disturbances in non-obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Fertil Steril. 2019 Jan;111(1):168-77.Full text Abstract
205. Anagnostis P, Paparodis RD, Bosdou JK, et al. Risk of type 2 diabetes mellitus in polycystic ovary syndrome is associated with obesity: a meta-analysis of observational studies. Endocrine. 2021 Nov;74(2):245-53. Abstract
206. Conn JJ, Jacobs HS, Conway GS. The prevalence of polycystic ovaries in women with type 2 diabetes mellitus. Clin Endocrinol (Oxf). 2000 Jan;52(1):81-6. Abstract
207. Cioana M, Deng J, Nadarajah A, et al. Prevalence of polycystic ovary syndrome in patients with pediatric type 2 diabetes: a systematic review and meta-analysis. JAMA Netw Open. 2022 Feb 1;5(2):e2147454.Full text Abstract
208. Long C, Feng H, Duan W, et al. Prevalence of polycystic ovary syndrome in patients with type 2 diabetes: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2022;13:980405.Full text Abstract
209. O'Kelly AC, Michos ED, Shufelt CL, et al. Pregnancy and reproductive risk factors for cardiovascular disease in women. Circ Res. 2022 Feb 18;130(4):652-72.Full text Abstract
210. Amiri M, Ramezani Tehrani F, Behboudi-Gandevani S, et al. Risk of hypertension in women with polycystic ovary syndrome: a systematic review, meta-analysis and meta-regression. Reprod Biol Endocrinol. 2020 Mar 17;18(1):23.Full text Abstract
211. Elsenbruch S, Benson S, Hahn S, et al. Determinants of emotional distress in women with polycystic ovary syndrome. Hum Reprod. 2006 Apr;21(4):1092-9.Full text Abstract
212. Ching HL, Burke V, Stuckey BG. Quality of life and psychological morbidity in women with polycystic ovary syndrome: body mass index, age and the provision of patient information are significant modifiers. Clin Endocrinol (Oxf). 2007 Mar;66(3):373-9. Abstract
213. Kaczmarek C, Haller DM, Yaron M. Health-related quality of life in adolescents and young adults with polycystic ovary syndrome: a systematic review. J Pediatr Adolesc Gynecol. 2016 Dec;29(6):551-7. Abstract
214. Wild RA. Long-term health consequences of PCOS. Hum Reprod Update. 2002 May-Jun;8(3):231-41.Full text Abstract
215. Cooney LG, Lee I, Sammel MD, et al. High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2017 May 1;32(5):1075-91. Abstract
216. Nasiri-Amiri F, Faramarzi M, Omidvar S, et al. Depression and anxiety in adolescents and young women with polycystic ovary syndrome: a systematic review and meta-analysis. Int J Adolesc Med Health. 2023 Jun 1;35(3):233-42. Abstract
217. Lee I, Cooney LG, Saini S, et al. Increased odds of disordered eating in polycystic ovary syndrome: a systematic review and meta-analysis. Eat Weight Disord. 2019 Oct;24(5):787-97.Full text Abstract
218. Davitadze M, Malhotra K, Khalil H, et al. Body image concerns in women with polycystic ovary syndrome: a systematic review and meta-analysis. Eur J Endocrinol. 2023 Aug 2;189(2):R1-9.Full text Abstract
219. Vgontzas AN, Legro RS, Bixler EO, et al. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness: role of insulin resistance. J Clin Endocrinol Metab. 2001 Feb;86(2):517-20.Full text Abstract
220. Fogel RB, Malhotra A, Pillar G, et al. Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2001 Mar;86(3):1175-80.Full text Abstract
221. Tasali E, Van Cauter E, Ehrmann DA. Relationships between sleep disordered breathing and glucose metabolism in polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 Jan;91(1):36-42.Full text Abstract
222. Mak W, Dokras A. Polycystic ovarian syndrome and the risk of cardiovascular disease and thrombosis. Semin Thromb Hemost. 2009 Oct;35(7):613-20. Abstract
223. Boulman N, Levy Y, Leiba R, et al. Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease. J Clin Endocrinol Metab. 2004 May;89(5):2160-5.Full text Abstract
224. Meyer ML, Malek AM, Wild RA, et al. Carotid artery intima-media thickness in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012 Mar-Apr;18(2):112-26.Full text Abstract
225. Osibogun O, Ogunmoroti O, Kolade OB, et al. A systematic review and meta-analysis of the association between polycystic ovary syndrome and coronary artery calcification. J Womens Health (Larchmt). 2022 Jun;31(6):762-71.Full text Abstract
226. Sun D, Wu Y, Ding M, et al. Comprehensive Meta-Analysis of Functional and Structural Markers of Subclinical Atherosclerosis in Women with Polycystic Ovary Syndrome. Angiology. 2022 Aug;73(7):622-634.Full text Abstract
227. Kazemi M, Kim JY, Parry SA, et al. Disparities in cardio metabolic risk between Black and White women with polycystic ovary syndrome: a systematic review and meta-analysis. Am J Obstet Gynecol. 2021 May;224(5):428-444.e8.Full text Abstract
228. Krentz AJ, von Mühlen D, Barrett-Connor E. Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with prevalent cardiovascular disease. Menopause. 2007 Mar-Apr;14(2):284-92.Full text Abstract
229. Iftikhar S, Collazo-Clavell ML, Roger VL, et al. Risk of cardiovascular events in patients with polycystic ovary syndrome. Neth J Med. 2012 Mar;70(2):74-80.Full text Abstract
230. Elting MW, Korsen TJ, Bezemer PD, et al. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod. 2001 Mar;16(3):556-60.Full text Abstract
231. Mani H, Levy MJ, Davies MJ, et al. Diabetes and cardiovascular events in women with polycystic ovary syndrome: a 20-year retrospective cohort study. Clin Endocrinol (Oxf). 2013 Jun;78(6):926-34. Abstract
232. Okoth K, Chandan JS, Marshall T, et al. Association between the reproductive health of young women and cardiovascular disease in later life: umbrella review. BMJ. 2020 Oct 7;371:m3502.Full text Abstract
233. Zhao L, Zhu Z, Lou H, et al. Polycystic ovary syndrome (PCOS) and the risk of coronary heart disease (CHD): a meta-analysis. Oncotarget. 2016 Jun 7;7(23):33715-21.Full text Abstract
234. Zhou Y, Wang X, Jiang Y, et al. Association between polycystic ovary syndrome and the risk of stroke and all-cause mortality: insights from a meta-analysis. Gynecol Endocrinol. 2017 Dec;33(12):904-10. Abstract
235. Ramezani Tehrani F, Amiri M, Behboudi-Gandevani S, et al. Cardiovascular events among reproductive and menopausal age women with polycystic ovary syndrome: a systematic review and meta-analysis. Gynecol Endocrinol. 2020 Jan;36(1):12-23. Abstract
236. Setji TL, Holland ND, Sanders LL, et al. Nonalcoholic steatohepatitis and nonalcoholic fatty liver disease in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2006 May;91(5):1741-7.Full text Abstract
237. Gambarin-Gelwan M, Kinkhabwala SV, Schiano TD, et al. Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol. 2007 Apr;5(4):496-501. Abstract
238. Cerda C, Perez-Ayuso RM, Riquelme A, et al. Nonalcoholic fatty liver disease in women with polycystic ovary syndrome. J Hepatol. 2007 Sep;47(3):412-7. Abstract
239. Rocha ALL, Faria LC, Guimarães TCM, et al. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: systematic review and meta-analysis. J Endocrinol Invest. 2017 Dec;40(12):1279-88. Abstract
240. Wu J, Yao XY, Shi RX, et al. A potential link between polycystic ovary syndrome and non-alcoholic fatty liver disease: an update meta-analysis. Reprod Health. 2018 May 10;15(1):77.Full text Abstract
241. Yao K, Zheng H, Peng H. Association between polycystic ovary syndrome and risk of non-alcoholic fatty liver disease: a meta-analysis. Endokrynol Pol. 2023;74(5):520-7. Abstract
242. Targher G, Rossini M, Lonardo A. Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis? Endocrine. 2016 Feb;51(2):211-21. Abstract
243. Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol. 2007 Nov;17(11):863-9. Abstract
244. Hardiman P, Pillay OC, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet. 2003 May 24;361(9371):1810-2. Abstract
245. Chittenden BG, Fullerton G, Maheshwari A, et al. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod Biomed Online. 2009 Sep;19(3):398-405. Abstract
246. Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod. 2012 May;27(5):1327-31.Full text Abstract
247. Cowan S, Grassi A, Monahan Couch L, et al. Evidence-based lifestyle guidelines and self-management strategies utilized by women with polycystic ovary syndrome. Nutrients. 2023 Jan 22;15(3):589.Full text Abstract
248. Haqq L, McFarlane J, Dieberg G, et al. The effect of lifestyle intervention on body composition, glycemic control, and cardiorespiratory fitness in polycystic ovarian syndrome: a systematic review and meta-analysis. Int J Sport Nutr Exerc Metab. 2015 Dec;25(6):533-40. Abstract
Use of this content is subject to our disclaimer